This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nekarda, H. Articles by Siewert, J. R. Search for Related Content PubMed PubMed Citation Articles by Nekarda, H. Articles by Siewert, J. R.

Prognostic Impact of Urokinase-type Plasminogen Activator and Its Inhibitor PAI-1 in Completely Resected Gastric Cancer¹

Chirurgische Klinik und Poliklinik [H. N., A. W., H. V., J. D. R., U. F., J. R. S.]; Frauenklinik [M. S.]; Institut für Medizinische Statistik und Epidemiologie [K. U.]; and Institut für Allgemeine Pathologie und Pathologische Anatomie [K. B.], Technische Universität München Ismaningerstr. 22, D-81675 München, Germany

The prognostic impact of the proteolytic factors urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) was evaluated in 76 completely resected gastric cancer patients enrolled in a prospective study. All patients underwent macroscopically and microscopically residual tumor-free resection (category R_o, Union International Contre Cancer, 1987). uPA and PAI-1 levels were quantified in detergent-extracted (Triton X-100) specimens of primary gastric tumors by enzyme-linked immmunosorbent assays. Median values of 1.57 ng uPA/mg protein were determined in tumor tissue extracts compared to 0.14 ng uPA/mg protein in normal mucosa. For PAI-1, 0.93 ng PAI-1/mg protein versus 0.09 ng PAI-1/mg protein was calculated. uPA levels in tumor tissue extracts were significantly correlated with vascular invasion, Laurén classification, and WHO classification, whereas PAI-1 levels showed a significant correlation with advanced lymph node involvement, depth of invasion, tumor stage, site of tumor, and the Laurén, Borrmann, and WHO classifications.

Elevated uPA and PAI-1 levels were found to be associated with poor prognosis. The optimal cutoff values indicating a group of patients with shorter survival were 1.5 ng uPA/mg protein and 1.25 ng PAI-1/mg protein, respectively (Classification and Regression Tree analysis). Patients with either high uPA or PAI-1 values were significantly associated with decreased survival (median time of survival was 23 months (high) versus 44 months (low). By univariate Cox regression analysis, it was shown that TNM categories, WHO classification, size of tumor, uPA and PAI-1 levels were all significantly associated with survival. However, in multivariate Cox regression analysis of these grouped variables, nodal status, PAI-1 levels, and WHO classification were the only independent prognostic factors. The relative risks of failure were 5-, 2.9-, and 2.4-fold, respectively. We conclude that PAI-1 and uPA positivity may serve as new prognostic factors in gastric cancer, predicting shorter survival even in clinically important subgroups of patients.

¹ Supported by the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe GR 280/4-1) and the Wilhelm-Sander Stiftung No. 92.016.01.

² To whom requests for reprints should be addressed, at Chirurgische Klinik der Technischen Universität München, Klinikum rechts der Isar, Ismaningerstr. 22, D-81675 München, Germany.

Received 12/13/93. Accepted 4/ 4/94.

This article has been cited by other articles:

				S. Kenny, C. Duval, S. J. Sammut, I. Steele, D. M. Pritchard, J. C. Atherton, R. H. Argent, R. Dimaline, G. J. Dockray, and A. Varro Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells Am J Physiol Gastrointest Liver Physiol, September 1, 2008; 295(3): G431 - G441. [Abstract] [Full Text] [PDF]

				G. D. Maurer, J. H. Leupold, D. M. Schewe, T. Biller, R. E. Kates, H.-M. Hornung, U. Lau-Werner, S. Post, and H. Allgayer Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1123 - 1132. [Abstract] [Full Text] [PDF]

				M. D. Sternlicht, A. M. Dunning, D. H. Moore, P. D.P. Pharoah, D. G. Ginzinger, K. Chin, J. W. Gray, F. M. Waldman, B. A.J. Ponder, and Z. Werb Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2107 - 2114. [Abstract] [Full Text] [PDF]

				J. R. Merchan, J. Tang, G. Hu, Y. Lin, W. Mutter, C. Tong, S. A. Karumanchi, S. J. Russell, and V. P. Sukhatme Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst, June 7, 2006; 98(11): 756 - 764. [Abstract] [Full Text] [PDF]

				D. M. Schewe, T. Biller, G. Maurer, I. A. Asangani, J. H. Leupold, E. R. Lengyel, S. Post, and H. Allgayer Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2{alpha}-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers Clin. Cancer Res., December 15, 2005; 11(24): 8538 - 8548. [Abstract] [Full Text] [PDF]

				V. Y. Shin, W. K.K. Wu, K.-M. Chu, H. P.S. Wong, E. K.Y. Lam, E. K.K. Tai, M. W.L. Koo, and C.-H. Cho Nicotine Induces Cyclooxygenase-2 and Vascular Endothelial Growth Factor Receptor-2 in Association with Tumor-Associated Invasion and Angiogenesis in Gastric Cancer Mol. Cancer Res., November 1, 2005; 3(11): 607 - 615. [Abstract] [Full Text] [PDF]

				S. J. Shin, K. O. Kim, M. K. Kim, K. H. Lee, M. S. Hyun, K. J. Kim, J. H. Choi, and H. S. Song Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 342 - 348. [Abstract] [Full Text] [PDF]

				K. Yamamoto, K. Takeshita, T. Kojima, J. Takamatsu, and H. Saito Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly Cardiovasc Res, May 1, 2005; 66(2): 276 - 285. [Abstract] [Full Text] [PDF]

				A. A.-R. Higazi, F. Ajawi, S. Akkawi, E. Hess, A. Kuo, and D. B. Cines Regulation of the single-chain urokinase-urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity Blood, February 1, 2005; 105(3): 1021 - 1028. [Abstract] [Full Text] [PDF]

				T. Sakakibara, K. Hibi, Y. Kodera, K. Ito, S. Akiyama, and A. Nakao Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Esophageal Squamous Cell Carcinoma Clin. Cancer Res., February 15, 2004; 10(4): 1375 - 1378. [Abstract] [Full Text] [PDF]

				A. W. Rijneveld, S. Florquin, P. Bresser, M. Levi, V. de Waard, R. Lijnen, J. S. Van der Zee, P. Speelman, P. Carmeliet, and T. van der Poll Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia Blood, August 1, 2003; 102(3): 934 - 939. [Abstract] [Full Text] [PDF]

				D. M. Schewe, J. H. Leupold, D. D. Boyd, E. R. Lengyel, H. Wang, K. U. Gruetzner, F. W. Schildberg, K. W. Jauch, and H. Allgayer Tumor-specific Transcription Factor Binding to an Activator Protein-2/Sp1 Element of the Urokinase-type Plasminogen Activator Receptor Promoter in a First Large Series of Resected Gastrointestinal Cancers Clin. Cancer Res., June 1, 2003; 9(6): 2267 - 2276. [Abstract] [Full Text] [PDF]

				M. M. Heiss, E. H. Simon, B. C.M. Beyer, K. U. Gruetzner, A. Tarabichi, R. Babic, F. W. Schildberg, and H. Allgayer Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow J. Clin. Oncol., April 15, 2002; 20(8): 2005 - 2016. [Abstract] [Full Text] [PDF]

				N. Sasaki, T. Morisaki, K. Hashizume, T. Yao, M. Tsuneyoshi, H. Noshiro, K. Nakamura, T. Yamanaka, A. Uchiyama, M. Tanaka, et al. Nuclear Factor-{kappa}B p65 (RelA) Transcription Factor Is Constitutively Activated in Human Gastric Carcinoma Tissue Clin. Cancer Res., December 1, 2001; 7(12): 4136 - 4142. [Abstract] [Full Text] [PDF]

				G. Konecny, M. Untch, J. Arboleda, C. Wilson, S. Kahlert, B. Boettcher, M. Felber, M. Beryt, S. Lude, H. Hepp, et al. HER-2/neu and Urokinase-Type Plasminogen Activator and Its Inhibitor in Breast Cancer Clin. Cancer Res., August 1, 2001; 7(8): 2448 - 2457. [Abstract] [Full Text] [PDF]

				D. J. Webb, K. S. Thomas, and S. L. Gonias Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes MCF-7 Cell Growth J. Cell Biol., February 20, 2001; 152(4): 741 - 752. [Abstract] [Full Text] [PDF]

				L. S. Gutierrez, A. Schulman, T. Brito-Robinson, F. Noria, V. A. Ploplis, and F. J. Castellino Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor-1 Cancer Res., October 1, 2000; 60(20): 5839 - 5847. [Abstract] [Full Text]

				G. Xiao, Y. E. Liu, R. Gentz, Q. A. Sang, J. Ni, I. D. Goldberg, and Y. E. Shi Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells PNAS, March 30, 1999; 96(7): 3700 - 3705. [Abstract] [Full Text] [PDF]

				A. A.-R. Higazi, K. Bdeir, E. Hiss, S. Arad, A. Kuo, I. Barghouti, and D. B. Cines Lysis of Plasma Clots by Urokinase-Soluble Urokinase Receptor Complexes Blood, September 15, 1998; 92(6): 2075 - 2083. [Abstract] [Full Text] [PDF]